Bioavailability (BA) / Bioequivalence (BE) in Pharma

begin with basic definitions for bioavailability and bioequivalence, identify active pharmaceutical ingredients, and illustrate finished products and dosage forms with examples of active pharmaceutical ingredients like paracetamol and sildenafil citrate.

Define reference listed drug, comparator product, brand name, and generic drugs, and show how efficacy, safety, and quality are established to demonstrate bioavailability and bioequivalence.

Explore pharmaceutical alternatives and pharmaceutical equivalence, illustrating how products may share the same API and moiety but differ in dosage form or salts, and the in vivo proof needed for bioequivalence.

Describe basic pharmaceutical bioequivalence and therapeutic equivalence, requiring the same molar API dose and similar in vivo efficacy and safety, demonstrated by PK/PD and clinical or in vitro studies.

Explore how IV and oral drug forms face solubility and permeability barriers in the GI tract, influencing bioavailability. Learn the biopharmaceutical classification system and class I–IV patterns for formulation strategies.

Define bioavailability as the fraction of drug reaching systemic circulation, highlighting IV 100% bioavailability and barriers in solid forms that affect Cmax and AUC.

Examine viability studies that compare an oral dosage form to a reference product using IV as 100% viability, to assess in vivo bioavailability, efficacy, and safety.

Explore the principles of bioequivalence and bioavailability, focusing on rate and extent of drug exposure, therapeutic windows, and safety versus efficacy in comparing two products.

Understand why bioequivalence studies justify new oral formulations by comparing test products to development formulations, highlighting absorption rate, extent, and therapeutic equivalence with generics.

Generic drug development uses in vitro solubility in solution conditions and the time to drug release percent graph alongside in vivo studies to demonstrate similarity of generic oral dosage forms.

Explain how bioavailability and bioequivalence are defined by the FDA, and how ADME processes shape PK metrics like AUC, Cmax, and Tmax to compare generic and reference products.

Compare Cmax, Tmax, and AUC using concentration-time curves to assess rate and extent of absorption, guiding bioequivalence decisions for oral drug products in vivo.

Explore how bioequivalence studies assess generic products against the reference listed drug by ensuring identical active substances and pharmaceutical form, and evaluating salts and isomers for safety and efficacy.

Explore the overview of bioequivalence study design, including parallel and crossover trials, randomized subjects, test product versus generic drug, and washout periods.

Explore the two-way crossover study design for bioequivalence, with randomization, test versus reference products, pharmacokinetic sampling, and key metrics like Cmax, AUC, and Tmax.

Use parallel study design to compare groups, randomizing subjects to test and reference treatments. Collect PK data over at least three half-lives to determine Cmax, Tmax, and AUC.

Compare crossover and parallel study designs in pharma, highlighting washout needs, carryover risk, study duration, and subject numbers for bioavailability and bioequivalence research.

Select study population to reflect patient demographics—age, sex, and race—among adults 18 and older, with a minimum of 12 subjects. Focus on absorption rate and extent, not therapeutic efficacy.

Standardize study conditions to minimize variability in bioavailability and bioequivalence studies, detailing diet, fluid intake, exercise, fasting eight hours pre-dose, fixed administration time, and no food for four hours post-dose.

Optimize sampling times to describe the plasma concentration time profile, capturing Cmax and Tmax with frequent around-predicted Tmax sampling and ensuring at least 80% of AUC.

Explore the biowaiver concept and the wherever approach to reduce in vivo bioequivalence studies by using in vitro conditions as a surrogate for drug products.

Explore the EMA guideline on bioequivalence waivers, outlining general criteria: same manufacturing process, identical qualitative and quantitative composition, proportionally related strengths, and in vitro data supporting waivers.

Apply second biowaiver criteria to 5 mg and 10 mg tablets, using in vitro dissolution similarity and active ingredient under 5% of core weight to waive in vivo bioequivalence testing.

Explore the third biowaiver criteria for bioavailability and bioequivalence by comparing 5 mg and 10 mg tablets with qualitative content but varying active amounts, supported by in vitro dissolution data.

Explore general biowaiver criteria for other dosage forms and evaluate bioequivalence requirements by dosage form, including tablets, capsules, oral suspensions, oral dispersible tablets, oral solutions, parenteral solutions, and emulsions.

Explore oral dispersible tablets and general bio waiver criteria, detailing buccal absorption versus GI absorption, and when BCS-based waivers apply or require human bioequivalence studies.

Evaluate general biowaiver criteria for oral solutions, including identical API concentrations with an approved solution and how excipients affect gastric transit, in vivo solubility, and BE decisions.

Explain when bioequivalence studies are waived (biowaiver) for parenteral solutions, and how identical active substance, concentration, and excipients affect pharmacokinetics across intravenous, intramuscular, and subcutaneous routes.

Explain general biowaiver criteria for emulsions, requiring identical qualitative and quantitative composition and similar physicochemical characteristics, including PSD of lipid phase, zeta potential, rheology, and same administration rate and method.

Conclude the bioavailability and bioequivalence in pharma course and invite learners to explore related topics on GMP, GLP, GHB, process validation, CTD preparation, dosage forms, and HPLC.